Condition: Diffuse Cutaneous Systemic Sclerosis · Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
The purpose of this study is to assess safety and efficacy of Brentuximab vedotin, a CD30-directed antibody-drug conjugate, in patients with active diffuse cutaneous systemic sclerosis (dcSSc) who relapsed after discontinuation of Brentuximab vedotin.
This description comes directly from the study's public registry record.
Janet E Pope, PhD · 519-646-6332 · Janet.Pope@sjhc.london.on.ca
Amanda Philip · 519-646-6000 · Amanda.Philip@sjhc.london.on.ca
Always discuss trial participation with your own doctor first.
| Rheumatology Clinic, St. Joseph's Health Care | London, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05149768